$ATYR
aTyr Pharma Inc

2015 Q4 Form 10-Q Financial Statement

#000156459015010357 Filed on November 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.810M $3.570M $1.820M
YoY Change 125.44% 96.15%
% of Gross Profit
Research & Development $12.67M $7.739M $4.410M
YoY Change 191.94% 75.49%
% of Gross Profit
Depreciation & Amortization $230.0K $220.0K $210.0K
YoY Change 9.52% 4.76% -59.62%
% of Gross Profit
Operating Expenses $16.48M $11.31M $6.231M
YoY Change 173.35% 81.56%
Operating Profit -$11.31M -$6.231M
YoY Change 81.56%
Interest Expense -$40.00K -$190.0K
YoY Change -84.62%
% of Operating Profit
Other Income/Expense, Net -$16.00K -$400.0K
YoY Change -96.0%
Pretax Income -$16.49M -$11.33M -$6.630M
YoY Change 173.01% 70.89%
Income Tax
% Of Pretax Income
Net Earnings -$16.49M -$11.33M -$6.631M
YoY Change 173.15% 70.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$9.700M -$6.704M -$4.118M
COMMON SHARES
Basic Shares Outstanding 23.65M 23.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.54M $108.8M $23.50M
YoY Change 500.85% 362.98%
Cash & Equivalents $53.03M $60.05M $18.74M
Short-Term Investments $42.51M $48.80M $4.700M
Other Short-Term Assets $2.400M $2.600M $600.0K
YoY Change 242.86% 333.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $97.95M $111.4M $24.00M
YoY Change 493.31% 364.09%
LONG-TERM ASSETS
Property, Plant & Equipment $1.793M $1.841M $2.100M
YoY Change -6.86% -12.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.80M $28.00M
YoY Change
Other Assets $118.0K $137.0K $600.0K
YoY Change -94.66% -77.17%
Total Long-Term Assets $31.73M $29.99M $2.800M
YoY Change 667.23% 971.0%
TOTAL ASSETS
Total Short-Term Assets $97.95M $111.4M $24.00M
Total Long-Term Assets $31.73M $29.99M $2.800M
Total Assets $129.7M $141.4M $26.80M
YoY Change 528.15% 427.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.872M $1.590M $1.200M
YoY Change 170.2% 32.5%
Accrued Expenses $4.595M $3.569M $3.200M
YoY Change 56.72% 11.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.366M $3.300M $5.100M
YoY Change -34.0% -35.29%
Total Short-Term Liabilities $12.15M $8.776M $10.40M
YoY Change 20.12% -15.62%
LONG-TERM LIABILITIES
Long-Term Debt $1.776M $2.600M $5.900M
YoY Change -65.18% -55.93%
Other Long-Term Liabilities $571.0K $585.0K $800.0K
YoY Change 70.45% -26.88%
Total Long-Term Liabilities $2.347M $585.0K $6.700M
YoY Change 600.6% -91.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.15M $8.776M $10.40M
Total Long-Term Liabilities $2.347M $585.0K $6.700M
Total Liabilities $14.50M $9.361M $19.60M
YoY Change 38.73% -52.24%
SHAREHOLDERS EQUITY
Retained Earnings -$158.1M -$141.6M
YoY Change 43.55%
Common Stock $273.3M $270.9M
YoY Change 1322.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $115.1M $129.2M $7.200M
YoY Change
Total Liabilities & Shareholders Equity $129.7M $141.4M $26.80M
YoY Change 528.15% 427.5%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$16.49M -$11.33M -$6.631M
YoY Change 173.15% 70.85%
Depreciation, Depletion And Amortization $230.0K $220.0K $210.0K
YoY Change 9.52% 4.76% -59.62%
Cash From Operating Activities -$9.840M -$9.460M -$5.770M
YoY Change 69.66% 63.95% -55.62%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$390.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $4.020M $7.620M $650.0K
YoY Change 46.18% 1072.31%
Cash From Investing Activities $3.910M $7.240M $650.0K
YoY Change 42.18% 1013.85% -285.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.090M -790.0K -770.0K
YoY Change -39.11% 2.6% -101.52%
NET CHANGE
Cash From Operating Activities -9.840M -9.460M -5.770M
Cash From Investing Activities 3.910M 7.240M 650.0K
Cash From Financing Activities -1.090M -790.0K -770.0K
Net Change In Cash -7.020M -3.010M -5.890M
YoY Change 45.04% -48.9% -115.76%
FREE CASH FLOW
Cash From Operating Activities -$9.840M -$9.460M -$5.770M
Capital Expenditures -$110.0K -$390.0K $0.00
Free Cash Flow -$9.730M -$9.070M -$5.770M
YoY Change 67.76% 57.19% -54.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10113000
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA INC
dei Trading Symbol
TradingSymbol
LIFE
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3569000
CY2015Q3 us-gaap Loans Payable Current
LoansPayableCurrent
3307000
CY2014Q4 us-gaap Assets
Assets
20644000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1590000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1433000
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
319000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
445000
CY2014Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
5142000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
335000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
69000
CY2015Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
7285456
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
75772871
CY2015Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
73487415
CY2015Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
73487415
CY2015Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141631000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-68000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110151000
CY2015Q3 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
2640000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
211000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8776000
dei Document Type
DocumentType
10-Q
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
48750000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
1954000
CY2015Q3 us-gaap Long Term Investments
LongTermInvestments
28010000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
585000
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
95619000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31133000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17524000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-400000
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7739000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
24000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
129157000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141369000
CY2014Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3134000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
295000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270832000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1925000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2932000
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
310000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1841000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60053000
dei Amendment Flag
AmendmentFlag
false
CY2015Q3 us-gaap Assets Current
AssetsCurrent
111381000
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23648404
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2578000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
16509000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2210000
CY2015Q3 us-gaap Assets
Assets
141369000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.38
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-22.73
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23581001
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
843817
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-91010000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20644000
us-gaap Net Income Loss
NetIncomeLoss
-31480000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6631000
us-gaap Net Income Loss
NetIncomeLoss
-18312000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19209000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2014Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
95619000
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
66830
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10701863
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
65351
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1509249
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1509249
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95500000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23639280
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
909880
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23639280
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
909880
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4410000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21834000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12436000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3574000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1821000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9299000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5088000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
11313000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
6231000
us-gaap Operating Expenses
OperatingExpenses
31133000
us-gaap Operating Expenses
OperatingExpenses
17524000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11313000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6231000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-347000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-788000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-11329000
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
139000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
416000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11329000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6770000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31495000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18728000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.02
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13221551
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
824062
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11291000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6631000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31548000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18312000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
643000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
620000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
us-gaap Share Based Compensation
ShareBasedCompensation
2469000
us-gaap Share Based Compensation
ShareBasedCompensation
785000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
238000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
295000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-29000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
213000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-479000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-29000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-219000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-206000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1192000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
348000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
718000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-99000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26962000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17023000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
53580000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
85000
life Available For Sale Securities Contractual Maturity Period
AvailableForSaleSecuritiesContractualMaturityPeriod
P2Y
CY2015Q3 life Available For Sale Securities In Unrealized Loss Positions
AvailableForSaleSecuritiesInUnrealizedLossPositions
32
life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
545000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17722000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36457000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18735000
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
65782
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
99408000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5397000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24055000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
650000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-75898000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4996000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
75648000
life Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
77246000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
533000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
72000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2413000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
775000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
149014000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4297000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46154000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
CY2015Q3 life Number Of Variable Interest Entities
NumberOfVariableInterestEntities
6
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 5, 2015, the Company filed an amendment to its amended and restated certificate of incorporation to effect a one-for-7.95413 reverse stock split of the Company’s common stock (the Reverse Stock Split). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split.
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
7.95413
CY2015Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
58280
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10701863
life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2017-05
CY2011Q4 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P5Y
CY2015Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2015Q2 us-gaap Interest Paid
InterestPaid
500000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
149000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
610000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
231000
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
990000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1514471
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1141626
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
166454
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
413493
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2076150
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.60
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.38
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.29
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1050000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
474000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2469000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
785000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1192
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2015Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3813022
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11053954

Files In Submission

Name View Source Status
0001564590-15-010357-index-headers.html Edgar Link pending
0001564590-15-010357-index.html Edgar Link pending
0001564590-15-010357.txt Edgar Link pending
0001564590-15-010357-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20150930.htm Edgar Link pending
life-20150930.xml Edgar Link completed
life-20150930.xsd Edgar Link pending
life-20150930_cal.xml Edgar Link unprocessable
life-20150930_def.xml Edgar Link unprocessable
life-20150930_lab.xml Edgar Link unprocessable
life-20150930_pre.xml Edgar Link unprocessable
life-ex101_360.htm Edgar Link pending
life-ex311_7.htm Edgar Link pending
life-ex312_8.htm Edgar Link pending
life-ex321_9.htm Edgar Link pending
life-ex322_10.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending